JP2023508165A5 - - Google Patents
Info
- Publication number
- JP2023508165A5 JP2023508165A5 JP2022538879A JP2022538879A JP2023508165A5 JP 2023508165 A5 JP2023508165 A5 JP 2023508165A5 JP 2022538879 A JP2022538879 A JP 2022538879A JP 2022538879 A JP2022538879 A JP 2022538879A JP 2023508165 A5 JP2023508165 A5 JP 2023508165A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- expression
- mdm2 antagonist
- bap1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025122610A JP2025160292A (ja) | 2019-12-23 | 2025-07-22 | Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1919219.4 | 2019-12-23 | ||
| GBGB1919219.4A GB201919219D0 (en) | 2019-12-23 | 2019-12-23 | Cancer biomarkers |
| PCT/IB2020/062366 WO2021130682A2 (en) | 2019-12-23 | 2020-12-23 | Biomarkers for cancer therapy using mdm2 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122610A Division JP2025160292A (ja) | 2019-12-23 | 2025-07-22 | Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508165A JP2023508165A (ja) | 2023-03-01 |
| JP2023508165A5 true JP2023508165A5 (cg-RX-API-DMAC7.html) | 2024-01-09 |
Family
ID=69322948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538879A Pending JP2023508165A (ja) | 2019-12-23 | 2020-12-23 | Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー |
| JP2025122610A Pending JP2025160292A (ja) | 2019-12-23 | 2025-07-22 | Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122610A Pending JP2025160292A (ja) | 2019-12-23 | 2025-07-22 | Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー |
Country Status (14)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP2021505661A (ja) * | 2017-11-30 | 2021-02-18 | ジャズ ファーマシューティカルズ アイルランド リミテッド | アスパラギナーゼを用いた治療法 |
| JP2023539867A (ja) | 2020-08-27 | 2023-09-20 | 大塚製薬株式会社 | Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
| EP4255488A1 (en) * | 2020-12-01 | 2023-10-11 | Nanobiotix | Porous, high-z and carbon-free particles as radioenhancers |
| GB202103080D0 (en) * | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| EP4380691A1 (en) * | 2021-08-06 | 2024-06-12 | Institut Régional du Cancer de Montpellier (ICM) | Methods for the treatment of cancer |
| JP2025508016A (ja) * | 2022-03-04 | 2025-03-21 | 大鵬薬品工業株式会社 | Iapアンタゴニスト化合物を用いたがんの治療方法及び併用療法 |
| US20240217985A1 (en) * | 2022-12-22 | 2024-07-04 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF AN MDM2-p53 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS |
| CN118272524A (zh) * | 2022-12-30 | 2024-07-02 | 康方药业有限公司 | Cd74的医药用途 |
| WO2025235391A1 (en) * | 2024-05-06 | 2025-11-13 | University Of Massachusetts | P53 protein stabieizers inceuding mdm2 inhibitors as a "chemicae mastectomy" strategy in breast cancer brca1/2 mutation carriers |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6307035B1 (en) * | 1996-08-02 | 2001-10-23 | The Wistar Institute Of Anatomy And Biology | BRCA1 associated polynucleotide (BAP-1) and uses therefor |
| CN104876938A (zh) | 2009-11-12 | 2015-09-02 | 密歇根大学董事会 | 螺-吲哚酮mdm2拮抗剂 |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US10344333B2 (en) | 2011-02-18 | 2019-07-09 | Institute For Cancer Research | Methods for diagnosing a predisposition to develop cancer |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| RU2015133939A (ru) | 2013-02-21 | 2017-03-27 | Ф. Хоффманн-Ля Рош Аг | Асимметрический синтез замещенного пирролидин-2-карбоксамида |
| MA53572A1 (fr) | 2013-06-10 | 2021-10-29 | Amgen Inc | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
| RU2015154097A (ru) | 2013-06-24 | 2017-07-26 | Ф. Хоффманн-Ля Рош Аг | Стабильный внутривенный препарат |
| AU2014286237B2 (en) * | 2013-07-03 | 2020-08-20 | F. Hoffmann-La Roche Ag | mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| TWI635089B (zh) | 2013-09-04 | 2018-09-11 | 第一三共股份有限公司 | 螺氧基吲哚衍生物之製造方法 |
| US9657351B2 (en) * | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| CN115368356B (zh) * | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| AU2015247646B2 (en) | 2014-04-17 | 2019-06-06 | The Regents Of The University Of Michigan | MDM2 inhibitors and therapeutic methods using the same |
| CN106795561B (zh) * | 2014-06-19 | 2021-04-16 | 纪念斯隆-凯特琳癌症中心 | 用于对ezh2抑制剂的应答的生物标志物 |
| JP2017532959A (ja) | 2014-10-09 | 2017-11-09 | 第一三共株式会社 | Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| US20190038633A1 (en) | 2016-02-08 | 2019-02-07 | Epizyme, Inc. | Methods of treating cancer |
| EP3440082A1 (en) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| WO2017205786A1 (en) | 2016-05-27 | 2017-11-30 | Aileron Therapeutics, Inc. | Cell permeable peptidomimetic macrocycles |
| GB201615842D0 (en) | 2016-09-16 | 2016-11-02 | Ucl Business Plc | Cell death biomarker |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
-
2019
- 2019-12-23 GB GBGB1919219.4A patent/GB201919219D0/en not_active Ceased
-
2020
- 2020-12-23 CN CN202080096246.7A patent/CN115066614A/zh active Pending
- 2020-12-23 WO PCT/IB2020/062366 patent/WO2021130682A2/en not_active Ceased
- 2020-12-23 TW TW109145725A patent/TW202135803A/zh unknown
- 2020-12-23 KR KR1020227024749A patent/KR20220119423A/ko active Pending
- 2020-12-23 BR BR112022012444A patent/BR112022012444A2/pt unknown
- 2020-12-23 AU AU2020414482A patent/AU2020414482A1/en active Pending
- 2020-12-23 US US17/757,843 patent/US20230338337A1/en active Pending
- 2020-12-23 JP JP2022538879A patent/JP2023508165A/ja active Pending
- 2020-12-23 IL IL293934A patent/IL293934A/en unknown
- 2020-12-23 CA CA3162624A patent/CA3162624A1/en active Pending
- 2020-12-23 EP EP20830342.0A patent/EP4081801A2/en active Pending
- 2020-12-23 MX MX2022007876A patent/MX2022007876A/es unknown
- 2020-12-23 PH PH1/2022/551443A patent/PH12022551443A1/en unknown
-
2025
- 2025-07-22 JP JP2025122610A patent/JP2025160292A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7153775B2 (ja) | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 | |
| Moneta et al. | Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features | |
| US10626180B2 (en) | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease | |
| JP6038128B2 (ja) | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー | |
| EP2337864B1 (en) | Biomarkers for predicting the development of chronic autoimmune diseases | |
| JP2024508895A5 (cg-RX-API-DMAC7.html) | ||
| CA2988673A1 (en) | Epigenetic chromosome interactions | |
| Higham et al. | Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease | |
| JP5706817B2 (ja) | ループスのためのバイオマーカー | |
| JP2023539867A5 (cg-RX-API-DMAC7.html) | ||
| JP2026002914A (ja) | 乾癬治療における抗腫瘍壊死因子療法に対する応答性を判定するための方法 | |
| Pisani et al. | Proteomic insights on the metabolism in inflammatory bowel disease | |
| Bolko et al. | Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis | |
| de Montai et al. | Interferon-α biological activity is associated with disease activity and risk of flare in cutaneous lupus erythematosus: a monocentric study of 184 patients | |
| US20170145501A1 (en) | Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response | |
| EP3417291B1 (en) | Anti-cxc chemokine receptor antibodies and c-x-c chemokines for the diagnosis of autoimmune disease and graft-versus-host disease | |
| Mori et al. | Contribution of HLA-DRB1* 04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis | |
| EP2954325B1 (en) | Diagnosis of rheumatoid arthritis | |
| Koca et al. | Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet's disease | |
| Asgari et al. | Antibodies against interferon-beta in neuromyelitis optica patients | |
| CN104105967B (zh) | 生腱蛋白c及其在类风湿关节炎的用途 | |
| Nishijima et al. | Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis. | |
| US11779643B2 (en) | Methods and compositions for the treatment of an inflammatory bowel disease | |
| WO2019208542A1 (ja) | スティル病と敗血症との鑑別用バイオマーカー | |
| WO2018020060A1 (es) | Método para predecir la respuesta clínica a un tratamiento con agentes antiinflamatorios |